問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Neurology

更新時間:2023-11-03

李宜中Lee, Yi-Chun
  • Principal Investigator
  • Clinical Trial Experience (year) 21 years 10 個月

篩選

List

32Cases

2021-04-01 - 2026-03-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-01-01 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-12-15 - 2028-06-30

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
  • Condition/Disease

    Transthyretin amyloid cardiomyopathy

  • Test Drug

    ALXN2220

Participate Sites
5Sites

Recruiting5Sites

2021-11-01 - 2028-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2008-12-01 - 2011-11-30

Phase III

A randomised, double-blind, parallel-group placebo-controlled phase Ill study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke
  • Condition/Disease

    Ischemic stroke

  • Test Drug

    Desmoteplase

Participate Sites
6Sites

Terminated6Sites

2013-12-01 - 2018-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-04-01 - 2023-06-30

Phase III

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran
  • Condition/Disease

    ATTR patients with symptomatic polyneuropathy (FAP)

  • Test Drug

    Patisiran

Participate Sites
2Sites

Terminated2Sites

2020-02-01 - 2023-12-15

Phase III

A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
  • Condition/Disease

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  • Test Drug

    ION-682884 Injection; Inotersen (ISIS 420915) Injection

Participate Sites
4Sites

Recruiting4Sites

2020-02-01 - 2021-09-15

Phase III

A Phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis.
  • Condition/Disease

    generalized myasthenia gravis

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Recruiting5Sites

2020-05-01 - 2021-12-27

Phase III

A randomized, open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in adult patients with generalized myasthenia gravis
  • Condition/Disease

    myasthenia gravis

  • Test Drug

    Rozanolixizumab

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting1Sites

Study ended1Sites

1 2 3 4